Suppr超能文献

减毒单核细胞增生李斯特菌actA突变体诱导保护性CD8+ T淋巴细胞

Induction of protective CD8+ T lymphocytes by an attenuated Listeria monocytogenes actA mutant.

作者信息

Goossens P L, Milon G

机构信息

Unité d'Immunophysiologie Cellulaire, Institut Pasteur, Paris, France.

出版信息

Int Immunol. 1992 Dec;4(12):1413-8. doi: 10.1093/intimm/4.12.1413.

Abstract

We tested the ability of an attenuated actA mutant of Listeria monocytogenes to induce protective immunity in mice. This mutant can enter and multiply in the cytosol of the infected host cell, but is deficient in actin-dependent cell-to-cell spread. It was found to be of attenuated virulence for inbred C3H mice: the LD50 after i.v. injection was 1000-fold higher than that of the wild-type strain. Mutant bacteria multiplied up to the fourth day in the liver, but only for 1 day in the spleen. A single infection with the maximum sublethal dose of the actA mutant induced long-lasting immunity; the LD50 of virulent wild-type L. monocytogenes increased 100-fold and growth of wild-type L. monocytogenes was controlled in liver and spleen of these mice. The presence of Listeria-reactive T cells in spleen of C3H mice infected 7 days previously with the actA mutant was monitored, through their ability to protect naive syngeneic recipients against wild-type L. monocytogenes. Protection was mainly conferred by Thy-1+ CD8+ T lymphocytes; depletion of CD4+ T cells had no significant effect on the level of transferred protection. Such attenuated mutants may be used to develop live vector vaccines for delivery of heterologous proteins into the cytosol, thereby favoring the induction of a CD8+ T cell response.

摘要

我们测试了单核细胞增生李斯特菌的一种减毒actA突变体在小鼠中诱导保护性免疫的能力。该突变体能够进入被感染宿主细胞的胞质溶胶并在其中增殖,但在肌动蛋白依赖性的细胞间传播方面存在缺陷。结果发现它对近交系C3H小鼠的毒力减弱:静脉注射后的半数致死剂量(LD50)比野生型菌株高1000倍。突变细菌在肝脏中繁殖至第四天,但在脾脏中仅繁殖一天。用最大亚致死剂量的actA突变体进行单次感染可诱导持久免疫;强毒野生型单核细胞增生李斯特菌的LD50增加了100倍,并且在这些小鼠的肝脏和脾脏中野生型单核细胞增生李斯特菌的生长受到控制。通过它们保护同基因未感染受体抵抗野生型单核细胞增生李斯特菌的能力,监测了7天前感染actA突变体的C3H小鼠脾脏中李斯特菌反应性T细胞的存在情况。保护作用主要由Thy-1 + CD8 + T淋巴细胞介导;CD4 + T细胞的耗竭对转移的保护水平没有显著影响。这种减毒突变体可用于开发活载体疫苗,以便将异源蛋白递送至胞质溶胶,从而有利于诱导CD8 + T细胞反应。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验